T-cell epitopes within the complementarity-determining and framework regions of the tumor-derived immunoglobulin heavy chain in multiple myeloma

Blood

Volumn 101, Issue 12, 2003, Pages 4930-4936

  Hansson, Lotta ^b   Rabbani, Hodjattallah ^b   Fagerberg, Jan ^b   Österborg, Anders ^a   Mellstedt, Håkan ^b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CANCER ANTIBODY; EPITOPE; GAMMA INTERFERON; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN IDIOTYPE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;

ADULT; AGED; AMINO ACID SEQUENCE; ANTIGEN ANTIBODY REACTION; ANTIGEN BINDING; ANTIGEN RECOGNITION; ARTICLE; BINDING AFFINITY; BIOINFORMATICS; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; DATA BASE; DNA FLANKING REGION; HALF LIFE TIME; HAPLOTYPE; HUMAN; HUMAN CELL; IMMUNOGLOBULIN STRUCTURE; MOLECULAR BIOLOGY; MOLECULAR RECOGNITION; MULTIPLE MYELOMA; NUCLEOTIDE SEQUENCE; PREDICTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; T LYMPHOCYTE;

EID: 0037707274     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-04-1250     Document Type: Article

References (39)

1. Mellstedt H, Holm G, Bjorkholm M. Multiple myeloma, Waldenstrom's macroglobulinemia, and benign monoclonal gammopathy: characteristics of the B cell clone, immunoregulatory cell populations and clinical implications. Adv Cancer Res. 1984;41:257-289.
2. Weiss S, Bogen B. B-lymphoma cells process and present their endogenous immunoglobulin to major histocompatibility complex-restricted T cells. Proc Natl Acad Sci U S A. 1989;86:282-286.
3. Bogen B, Weiss S. Processing and presentation of idiotypes to MHC-restricted T cells. Int Rev Immunol. 1993;10(4):337-355.
4. Lynch RG. Immunoglobulin-specific suppressor T cells. Adv Immunol. 1987;40:135-151.
5. Osterborg A, Yi Q, Bergenbrant S, Holm G, Lefvert AK, Mellstedt H. Idiotype-specific T cells in multiple myeloma stage I: an evaluation by four different functional tests. Br J Haematol. 1995;89:110-116.
6. Yi Q, Osterborg A. Idiotype-specific T cells in multiple myeloma: targets for an immunotherapeutic intervention? Med Oncol. 1996;13:1-7.
7. + T cells. Blood. 2000;96:2828-2833.
8. Wen Y, Barlogie B, Yi Q. Idiotype-specific cytotoxic T lymphocytes in multiple myeloma: evidence for their capacity to lyse autologous primary tumor cells. Blood. 2001;97:1750-1755.
9. Fagerberg J, Yi Q, Gigliotti D, et al. T-cell-epitope mapping of the idiotypic monoclonal IgG heavy and light chains in multiple myeloma. Int J Cancer. 1999;80:671-680.
10. Wen YJ, Lim SH. T cells recognize the VH complementarity-determining region 3 of the idiotypic protein of B cell non-Hodgkin's lymphoma. Eur J Immunol. 1997;27:1043-1047.
11. Rezvany MR, Jeddi-Tehrani M, Rabbani H, et al. Autologous T lymphocytes recognize the tumour-derived immunoglobulin VH-CDR3 region in patients with B-cell chronic lymphocytic leukaemia. Br J Haematol. 2000;111:230-238.
12. Trojan A, Schultze JL, Witzens M, et al. Immunoglobulin framework-derived peptides function as cytotoxic T-cell epitopes commonly expressed in B-cell malignancies. Nat Med. 2000;6:667-672.
13. Bendandi M, Gocke CD, Kobrin CB, et al. Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nat Med. 1999;5:1171-1177.
14. Osterborg A, Yi Q, Henriksson L, et al. Idiotype immunization combined with granulocyte-macrophage colony-stimulating factor in myeloma patients induced type I, major histocompatibility complex-restricted, CD8- and CD4-specific T-cell responses. Blood. 1998;91:2459-2466.
15. Durie BG, Salmon SE. A clinical staging system for multiple myeloma: correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer. 1975;36:842-854.
16. Bergenbrant S, Yi Q, Osby E, et al. Anti-idiotypic B lymphocytes in patients with monoclonal gammopathies. Scand J Immunol. 1994;40:216-220.
17. Deane M, Norton JD. Immunoglobulin gene 'fingerprinting': an approach to analysis of B lymphoid clonality in lymphoproliferative disorders. Br J Haematol. 1991;77:274-281.
18. Schettino EW, Chai SK, Kasaian MT, Schroeder HW Jr, Casali P. VHDJH gene sequences and antigen reactivity of monoclonal antibodies produced by human B-1 cells: evidence for somatic selection. J Immunol. 1997;158:2477-2489.
19. Gulukota K, Sidney J, Sette A, DeLisi C. Two complementary methods for predicting peptides binding major histocompatibility complex molecules. J Mol Biol. 1997;267:1258-1267.
20. Fields GB, Noble RL. Solid-phase peptide synthesis utilizing 9-fluorenyl methoxycarbonynyl amino acids. Int J Pept Protein Res. 1990;35:161-214.
21. Zsigo J, Saneii H. A facile efficient method for the simultaneous synthesis of high-quality individual peptides: application of ACT Model 350 for rapid multiple synthesis of peptides by Solid-phase method. In: Hodges RS, Smith JA, eds. Peptides: Chemistry, Structure, and Biology. Proceedings of the Thirteenth American Peptide Symposium, Vol. 4. Leiden, the Netherlands: Escom; 1994.
22. Yi Q, Bergenbrant S, Osterborg A, et al. T-cell stimulation induced by idiotypes on monoclonal immunoglobulins in patients with monoclonal gammopathies. Scand J Immunol. 1993;38:529-534.
23. Fagerberg J, Steinitz M, Wigzell H, Askelof P, Mellstedt H. Human anti-idiotypic antibodies induced a humoral and cellular immune response against a colorectal carcinoma-associated antigen in patients. Proc Natl Acad Sci U S A. 1995;92:4773-4777.
24. + subsets. Br J Haematol. 1997;96:338-345.
25. Rossmann ED, Lewin N, Jeddi-Tehrani M, Osterborg A, Mellstedt H. Intracellular T cell cytokines in patients with B cell chronic lymphocytic leukaemia (B-CLL). Eur J Haematol. 2002;68:299-306.
26. Yi Q, Osterborg A, Bergenbrant S, Mellstedt H, Holm G, Lefvert AK. Idiotype-reactive T-cell subsets and tumor load in monoclonal gammopathies. Blood. 1995;86:3043-3049.
27. Yi Q, Dabadghao S, Osterborg A, Bergenbrant S, Holm G. Myeloma bone marrow plasma cells: evidence for their capacity as antigen-presenting cells. Blood. 1997;90:1960-1967.
28. Wen YJ, Min R, Tricot G, Barlogie B, Yi Q. Tumor lysate-specific cytotoxic T lymphocytes in multiple myeloma: promising effector cells for immunotherapy. Blood. 2002;99:3280-3285.
29. Sze DM, Giesajtis G, Brown RD, et al. Clonal cytotoxic T cells are expanded in myeloma and reside in the CD8(+)CD57(+)CD28(-) compartment. Blood. 2001;98:2817-2827.
30. Dabadghao S, Bergenbrant S, Anton D, He W, Holm G, Yi Q. Anti-idiotypic T-cell activation in multiple myeloma induced by M-component fragments presented by dendritic cells. Br J Haematol. 1998;100:647-654.
31. Cui Y, Chang LJ. Computer-assisted, quantitative cytokine enzyme-linked immunospot analysis of human immune effector cell function. Biotechniques. 1997;22:1146-1149.
32. Disis ML, Rinn K, Knutson KL, et al. Flt3 ligand as a vaccine adjuvant in association with HER-2/neu peptide-based vaccines in patients with HER-2/neu-overexpressing cancers. Blood. 2002;99:2845-2850.
33. Schaed SG, Klimek VM, Panageas KS, et al. T-cell responses against tyrosinase 368-376(370D) peptide in HLA(*)A0201 (+) melanoma patients: randomized trial comparing incomplete Freund's adjuvant, granulocyte macrophage colony-stimulating factor, and QS-21 as immunological adjuvants. Clin Cancer Res. 2002;8:967-972.
34. Harig S, Witzens M, Krackhardt AM, et al. Induction of cytotoxic T-cell responses against immunoglobulin V region-derived peptides modified at human leukocyte antigen-A2 binding residues. Blood. 2001;98:2999-3005.
35. Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol. 1994;12:991-1045.
36. Clemens A, Rademaekers A, Specht C, Kolsch E. The J558 VH CDR3 region contributes little to antibody avidity; however, it is the recognition element for cognate T cell control of the alpha(1→3) dextran-specific antibody response. Int Immunol. 1998;10:1931-1942.
37. Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood. 1999;94:1848-1854.
38. Zamoyska R. CD4 and CD8: modulators of T-cell receptor recognition of antigen and of immune responses? Curr Opin Immunol. 1998;10:82-87.
39. + T cell responses in antitumor immunity. Curr Opin Immunol. 1998;10:588-594.